Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy

Nicoletto, Maria Ornella; Casarin, Alessandra; Baldoni, Alessandra; Rulli, Eliana; Tasca, Giulia; Baretta, Zora; Artioli, Grazia; Lombardi, Giuseppe; Cappetta, Alessandro; Floriani, Irene; Randon, Giovanni; Valpione, Sara; Litta, P.; Conte, Pierfranco; Mocellin, Simone; Aliberti, Camillo

doi:10.21873/anticanres.11256

Cited by 3 publications

(1 citation statement)

References 19 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1985, Markman et al showed that a high dose of intraperitoneal cisplatin (200 mg/m 2 ) and intraperitoneal cytosine arabinoside in combination with systemic sodium thiosulfate was feasible and safe with a clinical response in 16 of 52 patients [ 75 ]. Moreover, a retrospective analysis showed that intraperitoneal cisplatin and intraperitoneal paclitaxel resulted in improved survival compared to standard systemic chemotherapy [ 97 ]. The authors matched 33 IP-treated patients with 66 patients who underwent systemic therapy and found a survival advantage for patients who had no more than two previous treatment lines (HR 0.21, 95% CI 0.09–0.48, p < 0.001).…”

Section: Results Of Intraperitoneal Chemotherapy For Unresectable Per...mentioning

confidence: 99%

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Guchelaar

Noordman

Koolen

et al. 2023

Drugs

View full text Add to dashboard Cite

Malignancies of the peritoneal cavity are associated with a dismal prognosis. Systemic chemotherapy is the gold standard for patients with unresectable peritoneal disease, but its intraperitoneal effect is hampered by the peritoneal-plasma barrier. Intraperitoneal chemotherapy, which is administered repeatedly into the peritoneal cavity through a peritoneal implanted port, could provide a novel treatment modality for this patient population. This review provides a systematic overview of intraperitoneal used drugs, the performed clinical studies so far, and the complications of the peritoneal implemental ports. Several anticancer drugs have been studied for intraperitoneal application, with the taxanes paclitaxel and docetaxel as the most commonly used drug. Repeated intraperitoneal chemotherapy, mostly in combination with systemic chemotherapy, has shown promising results in Phase I and Phase II studies for several tumor types, such as gastric cancer, ovarian cancer, colorectal cancer, and pancreatic cancer. Two Phase III studies for intraperitoneal chemotherapy in gastric cancer have been performed so far, but the results regarding the superiority over standard systemic chemotherapy alone, are contradictory. Pressurized intraperitoneal administration, known as PIPAC, is an alternative way of administering intraperitoneal chemotherapy, and the first prospective studies have shown a tolerable safety profile. Although intraperitoneal chemotherapy might be a standard treatment option for patients with unresectable peritoneal disease, more Phase II and Phase III studies focusing on tolerability profiles, survival rates, and quality of life are warranted in order to establish optimal treatment schedules and to establish a potential role for intraperitoneal chemotherapy in the approach to unresectable peritoneal disease. Supplementary Information The online version contains supplementary material available at 10.1007/s40265-022-01828-7.

show abstract

Section: Results Of Intraperitoneal Chemotherapy For Unresectable Per...mentioning

confidence: 99%

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Guchelaar

Noordman

Koolen

et al. 2023

Drugs

View full text Add to dashboard Cite

show abstract

Surgical Management of Recurrent Epithelial Ovarian Cancer

Bhatt

Bakrin

Gléhen

2017

Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond

View full text Add to dashboard Cite

Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis

Tang

Huang

Zhang

et al. 2023

JCM

View full text Add to dashboard Cite

Objective: We aimed to compare the survival outcomes and adverse events of hyperthermic intraperitoneal chemotherapy (HIPEC), intraperitoneal chemotherapy (IP)and intravenous chemotherapy (IP)for primary advanced ovarian cancer. Methods: PubMed, CENTRAL (Cochrane Central Registry of Controlled Trials), Embase, Web of Science and Scopus were searched using multiple terms for primary advanced ovarian cancer, including randomized controlled trials and comparative studies in both Chinese and English (up to date 15 August 2022). Outcomes include overall survival, progression-free survival and adverse events. The data were pooled and reported as hazard ratio (HRs) with 95% confidence intervals. The Newcastle–Ottawa Scales were used to assess the risk of bias in the included comparative study. The Cochrane Collaboration’s Risk of Bias Tool was used for randomized controlled trials. Results: In total, 32 studies, including 6347 patients and 8 different platinum-based chemotherapy regimens, were included in this network meta-analysis. Our analysis results showed that HIPEC2 (carboplatin with area under the curve 10) exhibited a statistically significant OS benefit compared to IV, weekly dose-dense chemotherapy and HIPEC1 (cisplatin with 75/100 mg/m2). Intraperitoneal plus intravenous chemotherapy was associated with a statistically significantly better likelihood of overall survival compared to IV. For progression-free survival, our statistical results only suggest a better progression-free survival in ovarian cancer patients treated with HIPEC1 compared with weekly dose-dense chemotherapy. No evidence of difference was observed between the other comparison groups. Compared with the non-HIPEC group, HIPEC may had a higher incidence of electrolyte disturbances (≥grade 3). Conclusion: Our statistical analysis suggests that the groups receiving HIPEC2 had a better OS than the groups receiving IV, weekly dose-dense chemotherapy and HIPEC1. For PFS, our analysis only showed HIPEC1 is better than IV. Moreover, HIPEC may lead to a higher incidence of electrolyte disturbances (≥grade 3). HIPEC therapy for advanced ovarian cancer is currently controversial.

show abstract

Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy

Cited by 3 publications

References 19 publications

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Surgical Management of Recurrent Epithelial Ovarian Cancer

Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis

Contact Info

Product

Resources

About